Sodium-glucose cotransporter 2 inhibitors across cardio-reno-metabolic disease and body mass index: a meta-analysis of randomized controlled trials | Synapse
April 10, 2026
Sodium-glucose cotransporter 2 inhibitors across cardio-reno-metabolic disease and body mass index: a meta-analysis of randomized controlled trials
Key Points
This research aims to evaluate the effects of SGLT2 inhibitors on cardiovascular outcomes across various body mass indices.
Conducted a meta-analysis of randomized controlled trials
Included diverse cardiovascular and renal populations
Analyzed outcomes related to cardiovascular death and hospitalization
SGLT2 inhibitors significantly reduced cardiovascular death and heart failure hospitalization
These benefits were observed across all body mass index categories
Overall mortality was also reduced with SGLT2 inhibitors
Abstract
Across a broad CRM population, SGLT2i reduce cardiovascular death or HF hospitalization and all-cause death irrespective of BMI.